AtriCure to Participate in Upcoming Investor Conferences

AtriCure, Inc. (Nasdaq: ATRC), a prominent innovator in surgical solutions for atrial fibrillation (Afib) and related medical conditions, has announced its participation in two upcoming investor conferences. The company's management will be featured in a fireside discussion at the UBS Global Healthcare Conference, scheduled for November 10, 2025, at 2:00 PM Eastern Standard Time. Additionally, they will participate in a similar discussion at the Stifel 2025 Healthcare Conference on November 12, 2025, at 8:40 AM Eastern Standard Time. Those interested can tune in to live audio webcasts of these events through the "Investors" section of AtriCure’s website.

AtriCure is dedicated to advancing technology for the effective treatment of Afib, which impacts over 59 million individuals globally. Their innovative products are utilized by surgeons worldwide to mitigate the complications associated with Afib while also managing post-operative pain. Noteworthy advancements include the Isolator® Synergy™ Ablation System, the first medical device to secure FDA approval specifically for persistent Afib treatment. Moreover, AtriCure's AtriClip® Left Atrial Appendage Exclusion System is recognized as the leading device for managing left atrial appendage. The Hybrid AF™ Therapy offers a minimally invasive solution for patients suffering from long-standing persistent Afib, and their cryoICE cryoSPHERE® and cryoXT® probes are designed to provide temporary pain relief during various surgical procedures.

For more comprehensive information, stakeholders can explore AtriCure's offerings at AtriCure.com and follow their updates on X (Twitter) @AtriCure.

For further inquiries, contact AtriCure's CFO Angie Wirick or investor relations representative Marissa Bych.

AtriCure, Inc. (Nasdaq: ATRC), a prominent player in innovative surgical treatments for atrial fibrillation (Afib) and related conditions, is actively participating in two key investor conferences in November 2025: the UBS Global Healthcare Conference and the Stifel 2025 Healthcare Conference. This engagement presents a compelling opportunity for investors to gain insights into the company’s strategic direction and product pipeline.

Given Afib's prevalence, affecting over 59 million people globally, AtriCure's innovative solutions are well-positioned within a burgeoning market. The company’s Isolator® Synergy™ Ablation System, the first FDA-approved device for treating persistent Afib, and the AtriClip® Left Atrial Appendage Exclusion System, which is the most widely used LAA management device, highlight AtriCure’s commitment to addressing unmet medical needs.

As the company showcases its technological advancements at these conferences, investors should closely monitor management's discussions for updates on clinical trials, FDA approvals, and market penetration strategies. The anticipated discourse may shed light on AtriCure’s growth trajectory and potential catalysts, informing investors about any shifts in market dynamics or competitive positioning.

Moreover, the global focus on minimally invasive procedures like the Hybrid AF™ Therapy indicates a favorable trend towards patient-centric treatments. Investors might find AtriCure's diversification into post-operative pain management, such as its cryoICE cryoSPHERE® and cryoXT® probes, an attractive aspect, reflecting an innovative approach to enhancing surgical outcomes.

Investors are encouraged to engage with the live audio webcasts of these presentations, which can be accessed through AtriCure's investor relations page, to gain firsthand insights. With AtriCure's strong market presence and ongoing innovation, it remains a noteworthy consideration for investors seeking exposure to the evolving healthcare landscape.